567 results for "24版指南"

in 14.15 milliseconds.

• RNA-seq dataset of patient and healthy donors

  RNA-seq dataset on a patient (P) presenting with defects of immunity and three healthy donors (C1, C5, C6). This dataset contains raw and processed files from RNA-seq transcriptome analysis performed according to the Smart-seq2. There are 24 single-read (50 bp) fastq files, 6 per patient/donor consisting of 2 cell types and 3 replicates per cell type. There is one count matrix file generated using featureCounts against Ensembl v98 gene models.

  Dataset EGAD00001008371

• SAHGP Dataset

  HumanOmni25M-8v1-1

  Dataset EGAD00010001418

• omnix_tibet

  Himalayan population genetic study raw data (Tibet)

  Dataset EGAD00010001473

• OGVP_HC24_Controls

  Healthy adult volunteers and newborns recruited in various countries across Oceania.

  Dataset EGAD00010000953

• WhereAreYouFrom 517K

  Where Are You From? samples types at 517K SNP loci

  Dataset EGAD00010000952

• Pancreatic Cancer OICR

  ICGC DCC Release 24, PACA-CA Exome sequence

  Dataset EGAD00001003264

• Whole Genome Sequencing of Gingivo-buccal Cancer: ICGC-India Project_YR03

  Dataset EGAD00001004478

• Array_data_psychosis

  Array data from a family with high prevalence of psychosis

  Dataset EGAD00010002028

• Array_data

  Array data from a family with high prevalence of psychosis

  Dataset EGAD00010002030

• Methylation

  Illumina EPIC arrays Naevus Melanoma Spitz Case

  Dataset EGAD00010002312

• TP53_KO_RPE1_SNPs

  Allelic imbalance data for cell lines derived from RPE1 with TP53 knockout

  Dataset EGAD00010001566

• AML relapse targeted resequencing

  Raw data (fastq files) from targeted resequencing of AML patients at relapse

  Dataset EGAD00001002118

• Accelerated single cell seeding in relapsed multiple myeloma

  25 Whole genome sequencing data cases

  Dataset EGAD00001006119

• RNA Sequencing of AD OM cells exposed to traffic-related air pollutants

  Total RNA sequencing of olfactory mucosa (OM) cells derived from individuals diagnosed with Alzheimer's disease exposed to traffic-related ultrafine particles (UFPs) for 24-h and 72-h in submerged cultures. The UFPs used for exposures were: A0, A20 and Euro6. Exposures were compared to the corresponding blank samples.

  Study EGAS50000000448

• RNASeq from PC12 cell lines (derived from PPGL) cultivated under 21% (normoxia) and 1% (hypoxia) oxygen conditions.

  RNASeq fastq files from PC12 cells (derived from rat PPGL) were cultivated in normoxia conditions (37˚C, 5% CO2 and 21% O2 balanced with N2) or in hypoxia conditions in a hypoxic incubator (37˚C, 5% CO2 and 1% O2 balanced with N2), for short time (12h, 24h, and 48h) or prolonged time (36 days). Samples at each timepoint were cultured in triplicate (total 24 paired end fastq files). Sequencing was performed with the Illumina NovaSeq6000.

  Dataset EGAD50000001200

• Development of actionable molecular targets and/or biomarkers for prognostication and patient stratification in gynecological cancer based on whole-exome sequencing and epigenomic analysis

  We collected 92 endometrial hyperplasia lesions (48 non-atypical from 30 cases and 44 atypical from 24 cases) and matched normal tissues/whole blood. The purpose of this study is to develop actionable molecular targets and/or biomarkers for prognostication and patient stratification.

  Study JGAS000642

• Whole-exome sequencing of acute erythroid leukemia

  To clarify the genomic characteristics of acute erythroid leukemia (AEL), 24 AEL cases with matched controls were analyzed using whole exome sequencing. Based on the patterns of genetic alterations, AEL were divided into 4 subgroups. EPOR/JAK/STAT pathway are frequently affected in AEL and could be a therapeutic target.

  Study EGAS00001003696

• Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers

  This project includes RNA-sequencing data from human FSHD and control skeletal muscle biopsies. This project includes data from 28 FSHD patients (total 37 samples, including vastus lateralis and tibialis anterior muscles) and 12 control individuals (total 24 samples, including vastus lateralis and tibialis anterior muscles).

  Study EGAS00001005782

• SNP Array Data for EGAS00001004666

  SNP Array Data for EGAS00001004666

  Dataset EGAD00010002257

• Immediate Postoperative Minimal Residual Disease Detection with MAESTRO Predicts Recurrence and Survival in Head and Neck Cancer Patients Treated with Surgery

  We selected 24 patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who were surgically treated. MAESTRO, our ultrasensitive, tumor-informed, mutation enrichment sequencing assay, was applied in a pooled format (MAESTRO-Pool) to plasma samples collected from these patients at baseline (pre-op) and postoperatively. We show that detection of circulating tumor DNA (ctDNA) 1 to 9 days after surgery is associated with significantly worse survival. Many plasma samples also had tumor fractions detected below 100 parts-per-million, the detection limit for first-generation commercial assays, highlighting the need for more sensitive ctDNA assays. Here we provide whole genome sequencing of matched tumor biopsy and normal germline DNA from 24 patients that were used to identify somatic single nucleotide variants (SNVs) to be tracked using our MAESTRO-Pool assay.

  Study phs003981

• HPAH Genotyping data

  Genotyping data for 32 individuals from a family affected by HPAH

  Dataset EGAD00010001633

• SNParray_CASCADE

  Tumor and matched normal DNA profiling by SNP array

  Dataset EGAD00010002398

• Pancreatic Cancer OICR

  ICGC DCC Release 24, PACA-CA Whole Genome sequence merged alignments

  Dataset EGAD00001003270

• RHD_SA_HC24_Cases

  Definite and borderline rheumatic heart disease cases and patients with mild non-diagnostic valvulopathy recruited in Samoa

  Dataset EGAD00010000960

• Heart Failure Network - Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (HFN EXACT-BioLINCC)

  ObjectivesTo determine the effect of allopurinol after 24 weeks on a composite clinical endpoint that classifies subject's clinical status (improved, worsened, unchanged) in patients with heart failure and high uric acid levels.BackgroundMorbidity and mortality rates for patients with heart failure are high, despite guideline-recommended therapy. Heart failure is characterized by an imbalance between left ventricular (LV) performance and myocardial energy consumption. There is a growing body of evidence that suggests oxidative stress contributes to ventricular and vascular remodeling, and disease progression in heart failure. Targeting potential source(s) of oxidative stress, e.g. Xanthine oxidase (XO), was the focus of recent clinical trials and epidemiological studies. Increased XO activity has been shown to lead to production of superoxide and uric acid (UA). Serum uric acid levels are included in heart failure risk scores, and hyperuricemia is present in about 25% of patients with heart failure. Hyperuricemia is associated with exercise intolerance, reduced survival, and worsening symptoms. The EXACT-HF trial tested allopurinol, an inhibitor of XO, as a potential target therapy for hyperuricemic heart failure patients.Subjects253 subjects were enrolled in the EXACT-HF study. 128 participants were randomized to the allopurinol arm, and of those participants, 119 completed the trial and 9 did not. 125 participants were randomized to the placebo arm, and of those participants, 116 completed the trial and 9 did not.DesignEXACT-HF was a multi-center, double-blind, placebo controlled, 24-week trial of allopurinol. Eligible participants had to be receiving a stable regimen for at least two weeks (3 months for beta-blockers) prior to randomization. Participants were randomized by an automated system to either the allopurinol or placebo arm, and started treatment within 12 hours of completing the baseline visit. During the first week, participants in both treatment arms received 300mg daily of the respective medications. For the following 23 weeks, participants in both treatment arms received 600mg daily of the respective medications. Patients unable to tolerate 600 mg were maintained on 300 mg.The primary endpoint was a composite clinical endpoint (CCE) that classified a subject's clinical status as improved, worsened, or unchanged at 24 weeks. The CCE was determined based on the following: death; hospitalization, emergency room visit or emergent clinic visit for worsening HF; medication change for worsening HF; and Patient Global Assessment using a 7-point scale. Secondary endpoints at 12 and 24 weeks included changes in quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire, and submaximal exercise capacity as assessed by a 6-minute walk test.ConclusionsParticipants who received allopurinol had significantly less serum uric acid laboratory levels after 24 weeks; however, no significant difference was observed in the primary and secondary endpoints between the allopurinol and placebo-treated patients. Therefore, in high-risk HF patients with reduced ejection fraction and elevated uric acid levels, xanthine oxidase inhibition with allopurinol failed to improve clinical status, exercise capacity, quality of life, or LVEF at 24 weeks (Circulation. 2015 May 19; 131(20):1763-71).

  Study phs003533

• The genetic structure of Norway

  The genetic structure of Norway

  Dataset EGAD00010002032

• SPGRX_genotype

  Cohort: Raw genotype files for SPGRX cohort. Genotype Chip: the Illumina Global Screening Array-24 v3.0 genomic build: b38

  Dataset EGAD00010002176

• RNA-sequencing of N-ERD patients with Dupilumab therapy

  Transcriptomic profiles of Non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) patients before and after aspirin challenge during 24 weeks of Dupilumab therapy. To investigate the dynamics of nasal mediators during aspirin provocation in N-ERD patients before and twenty-four weeks after therapy with the IL-4 receptor alpha-blocking antibody dupilumab.

  Study EGAS50000000386

• Columbia Alzheimer's sample (white matter)

  The Columbia Alzheimer’s dataset (white matter) consists of 24 white matter individuals (12 controls, 12 cases). A total of 12,000 estimated cells from each sample were loaded on the 10x Single Cell Next GEM G Chip. cDNA libraries were prepared using the Chromium Single Cell 3’ Library and Gel Bead v3 kit according to the manufacturer’s instructions. cDNA libraries were sequenced using the Illumina NovaSeq 6000 System and NovaSeq 6000 S2 Reagent Kit v1.5 (100 cycles), aiming at a sequencing depth of minimum 30K reads/nucleus.

  Dataset EGAD00001009168

• NABUCCO cohort 1 (NCT03387761) - Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy

  NABUCCO cohort 1 sequencing data. The dataset includes: * Whole exome DNAseq pre-treatment on tumor samples (n=24) matched with blood samples (n=24) * RNAseq pre-treatment on tumor samples (n=18) * RNAseq post-treatment on tumor samples (n=18). Not all pre-treatment samples are linked with pre-treatment samples * High coverage Whole exome DNAseq on pre-treatment tumor samples (n=3) matched with post-treatment metastasized lymph nodes isolated with laser microdissection (n=3) * All samples are labelled with the response phenotype (Complete Responder or Non-Complete Responder)

  Dataset EGAD00001006250

• PDAC organoid genomic heterogeneity

  Two primary tumor-derived PDAC organoids were subjected to SNP array, RNA-seq, and single-cell WGS

  Dataset EGAD00010002408

• WES of bladder tumors from 24 patients

  This dataset contains 144 files fastq files sequenced with Illumina HiSeqX.

  Dataset EGAD50000001775

• WGBS files for PCGP NBL_MYCN_ATRX

  WGBS files for PCGP NBL_MYCN_ATRX paper titled "MYCN Amplification and ATRX Mutations are Incompatible in Neuroblastoma"

  Dataset EGAD00001004559

• RNA Transcriptomic and DNA Methylation Landscape in FTLD-TDP and Controls

  Frontotemporal lobar degeneration (FTLD) is one of the leading causes of dementia in individuals younger than 65 years, with the aggregation of TDP-43 as one of the most common forms of FTLD. FTLD-TDP is clinically, genetically and pathologically heterogeneous, with GRN and C9orf72 as the most common genetic forms (although more than 50% of the cases are genetically unexplained), and A, B and C as the most common pathological subtypes. To investigate the molecular differences between the different forms of FTLD-TDP, we performed bulk RNA sequencing (RNAseq) and reduced representation bisulfite sequencing (RRBS) from different brain regions of FTLD-TDP patients and controls. The RNAseq dataset includes samples from the frontal cortex of 149 individuals, comprising 127 FTLD-TDP cases (genetically unexplained types A (27), B (20) and C (22), 24 GRN mutation carriers, and 34 C9orf72 expansion carriers) and 22 controls. The RRBS dataset includes samples from the frontal cortex of 158 individuals —119 FTLD-TDP cases (genetically unexplained types A (25), B (24), and C (25), 20 GRN mutation carriers, and 25 C9orf72 expansion carriers) and 39 controls; and from the cerebellum of 151 individuals —113 FTLD-TDP cases (genetically unexplained types A (24), B (21), and C (23), 20 GRN mutation carriers, and 25 C9orf72 expansion carriers) and 38 controls. In total, the study consists of data from 183 unique individuals, with some overlap across the different datasets.

  Study phs004075

• BelCovid_2_genotype

  Cohort: Raw genotype files for BelCovid2 cohort. Genotype Chip: Illumina Global Screening Array-24 v3.0 + Multi-Disease beadchip genomic build: b37

  Dataset EGAD00010002179

• GEN_COVID_genotype

  Cohort: Raw genotype files for GEN_COVID cohort. Genotype Chip: Illumina Global Screening Array-24 v3.0 + Multi-Disease beadchip genomic build: b37

  Dataset EGAD00010002177

• Time course acetalax bisacodyl treatment

  RNA-Seq raw data of PDX treated with acetalaxor bisacodyl for 4h00 to 24h00.

  Dataset EGAD50000000875

• WGS data for MMML for Study EGAS00001002198

  Whole genome sequencing data for MMML (healthy cell_line)

  Dataset EGAD00001003283

• SPTCL exome data

  Whole exome sequencing data of 17 SPTCL cases, including 7 matched-normal samples.

  Dataset EGAD00001004310

• Ovarian cancer EV RNA-seq

  Ovarian cancer EV RNA-seq

  Dataset EGAD00001008972

• Germline variant analysis in childhood AML

  This dataset contains one vcf file with variants from whole exome sequencing of 24 paediatric AML samples at diagnosis.

  Dataset EGAD00001008783

• Targeted capture ctDNA Library CRCQV42Run017-15

  Targeted capture ctDNA Library CRCQV42Run017-15 from patient PBC0001673, plasma 24 month sample

  Dataset EGAD00001010407

• Targeted capture ctDNA Library CRCQV42Run036-14

  Targeted capture ctDNA Library CRCQV42Run036-14 from patient PBC0001653, plasma 24 month sample

  Dataset EGAD00001010596

• WGS of 8 trios - affected child and both normal parents

  WGS of 8 trios - affected child and both normal parents

  Dataset EGAD00001001467

• HGP-clean

  Himalayan population genetic study QC filtered data

  Dataset EGAD00010001471

• scWGS chordblood

  Single cell WGS (low pass) for chord blood samples

  Dataset EGAD00001006136

• Prostate WGS data (late onset)

  Whole genome sequencing for 12 late onset prostate cancer tumor/control pairs (ICGC)

  Dataset EGAD00001003290

• Complex Landscapes of Somatic Rearrangements in Human Breast Cancer Genomes

  We have used massively parallel paired end sequencing strategies to reconstruct the genomic landscape of 24 breast cancer genomes, through the identification and characterization of 2166 somatically acquired genomic rearrangements. These studies have revealed considerable complexity in the patterns of structural variation, identified novel fusion genes and unveiled new insights into the complex structure of amplicons.

  Study EGAS00000000062

• SARS-CoV-2 induced alterations of the upper airway DNA methylome exert long-term impacts on ciliary genes involved in ciliary function

  Enzymatic DNA methylome (n=33) and single-cell RNA (n=24) sequencing were performed in nasal cells of COVID-19 patients and controls. In addition, we re-sampled a subset of patients for transcriptome analyses at 3 and 12 months post-infection and followed the expression of differentially regulated genes over time.

  Study EGAS50000000273

• Whole-genome sequencing in gastric cancer (part2)

  we analysis structural variations (SVs) and mutational signatures via whole-genome sequencing of 168 GCs. Our data demonstrates diverse models of complex SVs operative in GC, which lead to high-level amplification of oncogenes. We find varying proportion of tandem-duplications (TDs) among individuals and identify 24 TD hotspots involving well-established cancer genes such as CCND1, ERBB2 and MYC.

  Study EGAS00001006575